| +0.02 / +0.09%|
NewLink Genetics Corp. is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. The company's product are: HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
|Charles J. Link||Chairman, Chief Executive & Scientific Officer|
|Nicholas N. Vahanian||President & Chief Medical Officer|
|Gordon H. Link||Chief Financial Officer & Secretary|
|W. Jay Ramsey||Clinical & Regulatory Compliance Officer|
|Brian Wiley||Vice President-Business Development|